Brain Scientific Inc.
BRSF · OTC
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.01 | 0.04 | -0.00 |
| FCF Yield | -1,005.30% | -11.77% | -17.13% | -11.64% |
| EV / EBITDA | -21.71 | -3.05 | -12.12 | -14.34 |
| Quality | ||||
| ROIC | 6.62% | -40.59% | -10.03% | -20.46% |
| Gross Margin | -127.13% | 64.50% | 1.29% | 33.16% |
| Cash Conversion Ratio | 0.38 | 0.32 | 0.71 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -26.68% | -9.31% | -10.41% | -11.94% |
| Free Cash Flow Growth | 13.22% | 19.10% | -18.62% | 51.54% |
| Safety | ||||
| Net Debt / EBITDA | -20.51 | -0.01 | 2.76 | -6.73 |
| Interest Coverage | 0.13 | -26.78 | -1.36 | -7.42 |
| Efficiency | ||||
| Inventory Turnover | 0.08 | 0.03 | 0.29 | 0.68 |
| Cash Conversion Cycle | -7,206.09 | -22,519.90 | -2,623.70 | -779.09 |